Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-101 eye drops for inhibition of corneal neovascularisation in infectious keratitis/keratouveitis
2004-005015-29Phase 2Terminated
- Sponsor
- Center for Testing and Research Services
- Start
- Sep 2005
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of aganirsen in corneal infection, infectious keratouveitis, corneal neovascularization (CNV), sponsored by Center for Testing and Research Services. Started Sep 2005; status: terminated.
02
Drugs
aganirsen
03
Conditions
corneal infectioninfectious keratouveitiscorneal neovascularization (CNV)
Beyond the preview
Go deeper on 2004-005015-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005015-29.